Your Partner in Pharmaceutical Development
PBI is dedicated to the development of therapeutics for the treatment of life-threatening diseases.
The Company's immuno-oncology PB307 biologic is designed to promote and harness the body's own immune system to destroy cancer cells. PB307 has been demonstrated in animal models to show dramatically increased tumor infiltrating lymphocytes (TILs) in tumor, significantly decreased immunosuppressive components in tumor, and tumor microenvironment modulation for enhancing cancer immunotherapy.
PB121 is an immune-oncology therapeutic. The improved PB121 cytokine formulation is developed to specifically activate NK cells and T effector cells as well as to overcome immunosuppressive components of the tumor microenvironment.
PB718 is developed for drug addiction treatment. This anti-addiction product is designed to prevent people who have certain drug addictions (e.g., opioids) from taking them again. For opioid addiction, it works in the brain to reduce and further prevent opiate effects. PB718 is formulated to reduce the symptoms of opiate withdrawal and minimize patient discomfort during the detox duration. PB718 is a novel next generation therapeutic providing solutions to treat both pain and addiction.
PB922 is an anti-inflammatory biological product. PB922 formulation is an enhanced biological system consisting of regulation of cytokines production and T cell proliferation. It is developed for the treatment of autoimmune diseases, including multiple sclerosis, Crohn's disease, ulcerative colitis, and rheumatoid arthritis.
PB844 is a specially formulated naturally occurring biologic and is developed for the treatment of neurologic disorders and neurodegenerative diseases.